Xunbaihui Bio Secures Tens of Millions of RMB in Seed Extension Round Led by IDG Capital to Advance Immuno-Oncology Drug Discovery

Investment Circle (WeChat ID: pedaily2012) reported on October 5 that GV20 Therapeutics, a company focused on the early-stage development of novel drugs for precision tumor immunotherapy by leveraging technologies such as big data mining in biology and high-throughput screening for gene editing, announced the completion of a funding round led by IDG Capital,Linear Capital, a follow-on seed financing round of tens of millions of RMB, with co-investment from Watson Capital and other individual existing shareholders.

This round of financing will continue to support GV20 Therapeutics’ technological reserves in big data analysis for biology and its progress in the development of novel immuno-oncology drugs.

GV20 Therapeutics was founded in Shanghai in 2016 by Dr. Xiaole Liu, a tenured full professor at Harvard University and the Dana-Farber Cancer Institute.Zhangjiang Pharma ValleyProfessor Liu Xiaole is a leading scientist in international biological big data and tumor functional genomics. He has served at Harvard University for over 15 years and previously chaired the review panel on genomics technology and computational biology for the U.S. National Institutes of Health (NIH). He has published nearly 200 scientific papers, including more than 50 in the Cell, Nature, and Science journals, and has mentored 16 individuals who have secured tenured professorships at universities and research institutions. The founding team of GV20 Therapeutics comprises experts in bioinformatics and cancer genomics from top-tier institutions such as Harvard University and Tongji University, boasting a robust talent pool.

It is reported that since its establishment over a year ago, GV20 Therapeutics has achieved multiple breakthroughs in both foundational technology development and oncology immunotherapy drug discovery. The company has established a comprehensive high-throughput gene-editing platform for drug target screening and data analysis, successfully identified several early-stage targets for cancer immunotherapy and advanced their development, and completed collaborative R&D projects with dozens of research institutions and pharmaceutical companies.

IDG Capital Continues to Monitor and SupportFrontier BiologicsDriven by the industrial translation of technological advancements and the development of tumor immunotherapy, IDG Capital participated in the investment in GV20 Therapeutics at its inception and led this round of financing.

In addition to tumor immunotherapy, IDG Capital has also extensively invested in otherPrecision Medicinetech startups in the field and provide them with continuous support, including Edigene, which focuses on gene therapy; Geneseeq, which specializes in precision diagnostics; Accutar Biotechnology, which leverages artificial intelligence for new drug design; and DeepPath AI, which applies artificial intelligence to pathological diagnosis.

This article is an original piece by the investment community, authored by rica. Original source: https://pe.pedaily.cn/201810/436378.shtml